Articles tagged with Breast Cancer Cells
Researchers found that excess estrogen levels during pregnancy can silence the BRCA1 tumor suppressor gene, increasing breast cancer risk in daughters. Additionally, molecular abnormalities in the unfolded protein response pathway were also found to contribute to breast cancer risk.
Researchers found that omega-3 fatty acids and their metabolites slow or stop the proliferation of triple-negative breast cancer cells, reducing growth by up to 90 percent. The effect was stronger in triple-negative cell lines, with reduced motility and apoptosis rates.
Research reveals Six2 homeoprotein promotes detachment of breast cancer cells from tissues, enabling their survival through the bloodstream and colonization at distant sites. Higher Six2 expression in human breast cancer tissues is associated with aggressive metastasis.
Triplet-negative breast cancer lacks receptors for progesterone, estrogen, and HER2/neu, making it difficult to treat. Researchers identified key metabolites that could help differentiate among subtypes and point to new treatment targets.
Research shows that inhibiting autophagy in breast cancers dependent on it may be enough alone to kill the disease. Chloroquine, an anti-malaria drug, has been found to inhibit autophagy and is being tested as a potential treatment for certain breast cancer subtypes.
Researchers found that Paragazole increases the sensitivity of triple-negative breast cancer cells to chemotherapy by inducing expression of estrogen receptors. The drug outperforms chemotherapy alone in a range of breast cancer cell lines, offering new hope for treatment options.
Researchers discovered SIRT4 plays a crucial role in preventing DNA damage-induced cancer by controlling glutamine metabolism and arresting cell cycle. In mice lacking SIRT4, lung cancer developed spontaneously, highlighting its potential as a therapeutic target.
Researchers have developed a multi-stage, multi-orifice flow fractionation system to detect and separate circulating tumor cells (CTCs) from blood with high efficiency, improving separation efficiency to 98.9%. The device, called MS-MOFF, employs hydrodynamic sorting and can collect viable CTCs after sorting.
Researchers have discovered that mutations in the TERT promoter gene are involved in some brain tumors and certain types of cancer. The study found nine tumor types highly associated with these mutations, which may provide a new target for drug development.
Researchers found that bitter melon juice restricts glucose metabolism and kills pancreatic cancer cells, cutting their energy source. The study used mouse models and showed a 60% reduction in disease development compared to controls.
Scientists at the University of Montreal's IRIC have identified a key mechanism that enables cancer cells to coordinate their movement, allowing them to disseminate efficiently in the body. By understanding this mechanism, researchers hope to develop molecular targets to disrupt collective cell migration and fight metastasis formation.
A new tool developed by EPFL researchers can accurately determine the optimal dose of chemotherapy for individual patients, reducing the risk of resistance mechanisms and relapse. The method measures a cancerous cell's electrical conductivity to assess the treatment's effect, allowing oncologists to make more patient-specific decisions.
A groundbreaking UK study found that aggressive triple-negative breast cancer cells lack the enzyme FBP1, leading to a glucose anabolic pathway that 'feeds' the cancer. This metabolic switch enables tumor cells to survive in low-oxygen environments, making it a promising target for new treatments.
A recent UEF study reveals that high cell sugar concentrations boost hyaluronan production, which can fuel cancer growth. Regulating hyaluronan levels may hold the key to preventing cancer progression.
A meta-analysis found that increased fascin-1 is associated with increased risk of mortality in breast, colorectal, and oesophageal carcinomas. Fascin-1 was also linked to disease progression and metastasis in some cases, but not others.
Breast cancer stem cells drive tumor progression and recurrence, making current treatments ineffective. Zolkiewska's research focuses on ADAM12, a promising marker that can help identify and target these cells for more effective treatments.
Researchers have identified FOXC2 as a protein vital to the formation of cancer stem cells and the epithelial-mesenchymal transition in breast cancer. The study found that blocking FOXC2 with the FDA-approved drug sunitinib inhibited the growth of cancer stem cells and reduced metastasis in mice with triple-negative breast cancer.
A Wayne State University researcher has identified characteristics in benign breast disease associated with future cancer risk in African-American women. The study found that women with proliferative breast disease with atypia were three times as likely to develop breast cancer.
A study published in the Journal of Clinical Investigation found that TGF-β is highly expressed in triple negative breast cancer cells after chemotherapy. In a mouse model, blocking TGF-β prevented tumor recurrence and enhanced chemotherapy action against triple negative breast cancer.
Studies reveal that blocking TGF-β can prevent tumor recurrence in mice with triple negative breast cancer. Additionally, targeting specific subsets of immune cells, such as CD8+ regulatory T-cells, may provide a new approach to treating rheumatoid arthritis.
A UCLA team developed a degradable nanoscale shell to carry proteins to cancer cells, stunting tumor growth and inducing cell death. The process is safer than traditional chemotherapy and gene therapies, preserving healthy cells.
Researchers developed a small-molecule inhibitor Y16 that blocks a hard-to-target part of a protein complex linked to several types of invasive cancer. The compound, combined with Rhosin/G04, suppresses RhoA cell signaling and downstream molecular events fueling cancer growth in breast cancer cells.
Researchers identified miR-7 as a metastasis suppressor that suppressed cancer stem-like cells' ability to metastasize to the brain. The miR-7/KLF4 axis played a critical role in cancer stem-like cell brain metastasis, suggesting its potential as a diagnostic or therapeutic target for predicting or treating brain metastases.
Researchers at the University of Pittsburgh Cancer Institute have found a way to halt cancer cell growth by depriving them of a key protein. By targeting this process, they discovered a potential new anti-cancer therapy that could work synergistically with existing drugs.
A team of researchers found that specific acetylation marks on histone H4 determine the balance between two proteins, BRCA1 and 53BP1, controlling DNA repair mechanisms. This balance affects a cell's ability to repair breaks and respond to chemotherapy.
Researchers have discovered a novel approach to fighting inflammatory breast cancer using quantum dots that deliver Vitamin D3, inhibiting invasion and migration of cancer cells. The therapy has shown promise in targeting tumor sites and visualizing the delivery of calcitriol through lymph systems.
Researchers at Walter and Eliza Hall Institute identify how pregnancy hormones alter DNA tags, controlling gene expression in breast cells. This discovery reveals a potential link between hormonal regulation and breast cancer risk, highlighting the importance of epigenome modifications.
The foundation awarded 15 Damon Runyon Fellows with $156,000 each to pursue novel ideas in cancer research. The recipients include Adam de la Zerda and Gabriel C. Lander, who aim to visualize signaling within tumors and characterize molecular machines in cells.
A University of Central Florida professor has discovered a protein present in several types of cancer that could help prevent tumors from coming back. The protein, KLF8, appears to protect tumor cells from drugs and aid their regeneration.
Breast cancer cells use pro-inflammatory signaling molecules to adhere to blood vessel surfaces, promoting metastasis. The Cornell researchers found that these cells are unable to interact with selectins, a key step in the process, and that inflammatory molecules enable them to adhere.
Researchers have identified a link between SNPs associated with breast cancer risk and the binding affinity of pioneer factor FOXA1. The study found that most risk-associated SNPs modulate FOXA1 binding, which is crucial for chromatin opening and transcription factor recruitment.
Researchers at LSUHSC have identified a new therapeutic target to block the function of Her2, a gene that promotes breast cancer progression and spread. The study also found that a novel protein called Nischarin regulates breast cancer cell migration and movement.
Researchers found that cancer cells lacking BRCA1 compensate by reducing 53BP1 levels, which allows them to resume homologous recombination and grow. The study suggests a new pathway for how breast cancer cells lose 53BP1, enabling resistance to chemotherapy and potentially identifying patients who respond to cathepsin inhibitors.
The Damon Runyon-Rachleff Innovation Award funds cancer research by exceptionally creative thinkers with 'high-risk/high-reward' ideas, selected through a rigorous process. Seven awardees aim to develop new approaches to fighting cancer, including virus-based treatments and single-cell sequencing tools.
A new study reveals how a 'transcription factor' called ELF5 causes aggressive breast cancer to develop, making it resistant to oestrogen therapies. Researchers found that manipulating ELF5 levels could be a potential treatment option for this type of breast cancer.
Scientists have discovered a vital interplay between transport machinery and integrin receptors that ensures proteins are transported to the correct area of the cell. This understanding could lead to better diagnosis for cancer patients as it reveals how cells become disorganized in early stages of the disease.
A new study challenges previous views on miR-205's function in breast cancer. Research found that miR-205 is overexpressed in transformed cells and contributes to the abnormal morphology of acini. The findings suggest miR-205 can act as an oncogene, promoting cell growth or inhibiting apoptosis.
Compression reverses abnormal growth in breast cancer cells, restoring normal development. The study's findings suggest that mechanical forces play a crucial role in determining a cell's fate.
Researchers found that breast cancer cells can reorganize into normal structures when exposed to compression force, suggesting a possible new approach to treating the disease. The study used 3D-matrix and elastic chamber to apply forces and observed significant changes in cell behavior.
Changes in progenitor cell populations in breast tissue may contribute to breast cancer development, according to new research. The study found that aging leads to a decrease in myoepithelial cells and an increase in multipotent progenitors, which can fuel malignant growth.
Researchers at University of Wisconsin-Madison discovered a new form of cell division called klerokinesis, which helps prevent faulty cell division leading to cancer. In experiments with human cells, they observed that cells with extra chromosomes could recover normal sets through klerokinesis, potentially lowering cancer incidence.
Researchers discovered HER2-positive breast cancer stem cells in previously thought HER2-negative tumors, making these cells resistant to traditional treatments. The findings suggest that targeted therapies can effectively treat HER2-negative breast cancers, while also providing a new diagnostic tool.
Researchers at the University of Michigan have devised a system to capture and study circulating tumor cells, which carry cancer around the body. The device uses nanoscale roughness to trap cancer cells regardless of their surface proteins or physical sizes.
Researchers have discovered a new therapy combination that targets the PI3K and JAK2/STAT5 pathways to combat aggressive metastatic breast cancer. In mouse studies, this approach led to slower tumor growth, reduced spread, and improved survival rates.
Researchers at Fox Chase Cancer Center developed a novel 3D culture system to mimic the environment surrounding IBC cells. The model showed that the tumor microenvironment promotes proliferation, growth and invasion of IBC tumors.
A clinical trial testing this hypothesis should begin soon, combining chemotherapy agents with a new approach to target the immune system. The study found that blocking negative immune system activation increases the efficiency of chemotherapy.
Researchers at the UNM Cancer Center are studying GPER, a novel estrogen receptor, to develop potential therapies for breast cancer. By understanding how GPER influences tumor growth and metastasis, they aim to create more effective treatments that can reduce resistance to existing drugs.
Researchers at the University of Iowa discovered that cancer cells are surprisingly resilient to fluid forces in the bloodstream, which could help improve liquid biopsy approaches for detecting cancer cells. The study's findings suggest that resistance to fluid shear stress may be a key characteristic of malignant cells.
Johns Hopkins researchers identified a protein called JMJD2C that helps breast cancer cells spread by unlocking genes. The discovery confirms the protein's role in breast cancer progression and offers a potential target for anti-cancer therapy.
Reintroducing miR-200c to aggressive triple-negative breast cancer cells restores sensitivity to anoikis, causing the cells to self-destruct. This approach shows promise as a less toxic alternative to chemotherapy.
Researchers have developed a solution to predict breast cancer cells' response to cancer drugs by analyzing their genomic profiles. The team's solution outperformed 47 other teams in a prediction challenge, taking an encouraging step forward for personalized medicine.
A new statistical image analysis method can assist in grading breast cancer by automatically segmenting tumour regions and detecting dividing cells. The method, developed at the University of Warwick, promises to bring objectivity and automation to the cancer grading process.
A recent study published in Nature Cell Biology has identified Elf5, a protein necessary for lactation, as a key player in suppressing breast cancer tumors and metastasis. The research found that when Elf5 is absent or low, epithelial cells become more like stem cells, leading to cancer growth and spread.
Researchers discover that breast cancer cells' ability to spread is influenced by the tumor's protein-rich environment as much as genetic changes within the cells. The study reveals that a specific molecular signal in the protein meshwork can initiate metastasis to distant sites, while a healthy environment can even coax healthy cells ...
Researchers developed a diagnostic tool identifying breast cancer cells' ability to spread, based on their lipid profile. The technique, Raman microspectroscopy, has shown promise for routine cytological diagnosis and may be extended to other tumors.
Researchers at Dana-Farber Cancer Institute have successfully shut down breast cancer and leukemia in mice by targeting abnormal proteins that control cell growth. The study found that inhibiting cyclin D1 or D3 proteins halts cancer growth, while normal cells remain unaffected.
Breast tumor cells interact with mesenchymal stem cells (MSCs) in the tumor microenvironment, triggering production of lysyl oxidase (LOX), a gene that enables cell migration and metastasis. This process, called epithelial-to-mesenchymal transition (EMT), allows cancer cells to spread to bones and other parts of the body.
Professor Sidney Fu is studying small RNA biomarkers to develop a blood test for detecting early-stage breast cancer. His research aims to identify patients who will not benefit from aggressive treatments, saving them from unnecessary trauma and stress.
Research identifies NF1 as a driver in more than 25% of non-inheritable breast cancers, associated with increased Ras activity and decreased NF1 levels. This finding may guide clinicians to targeted treatments for patients with NF1 mutations.
Research reveals activation of PI3K-Akt signaling pathway induces mammary gland cells to produce prolactin, triggering Stat5 activation and milk production. Prolactin's role in human breast cancer is reevaluated, with potential implications for treatment.